• Watchlist/Portfolio

    Add to watchlist:

    Only registered members can add into watchlist !

    Register here !

Medgenics is a clinical-stage biopharmaceutical company developing an innovative and proprietary platform technology - a biological "Biopump" - which allows patients to produce, within their bodies and on a long-term basis, their own natural human protein therapy for the treatment of a range of chronic diseases, such as anemia and hepatitis C.

Super Sector:
Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
EPIC / Symbols:
*subject to change and depends on individual circumstances.

Medgenics Articles, News, and Media Files

  • Page 1 of 7

Medgenics Related Media

  • Page 1 of 5
  • 11/10/2012

    Stocktube video - H₂0 Markets looks at AIM stocks

    Michael Jarman, Chief Market Strategist at H₂0 Markets looks at the reasons why the AIM index has outperformed the FT100 year to date. Mike also says why he likes Medgenics (LON:MEDG), which he says is a long term play, and also the opportunity that presents itself at New World Oil & Gas (LON:NEW) after the company recently raised money.

Director dealings

  • Page 1 of 7
Date Director Trans Amount Type Price(p) Value (£) Holding %
12/02/14 A.L. Pearlman EX 11,168 OPT 189.00 21,108 0,000 N/A
12/02/14 A.L. Pearlman SELL 11,168 ORD 500.00 55,840 42,375 0.35
04/02/14 A.L. Pearlman EX 20,000 OPT 0.00 0 0,000 N/A
04/02/14 A.L. Pearlman SELL 20,000 ORD 485.00 97,000 42,375 0.35
18/12/13 A.J.T. Clemow BUY 4,500 ORD 353.00 15,885 18,500 0.15

Company Statement


Medgenics is developing a unique sustained-action therapeutic protein delivery technology for the treatment of a range of chronic diseases. The technology – called a “Biopump” – is made from the patient’s own skin and is implanted in a simple procedure to work inside the patient’s body, to produce and deliver the active protein steadily over a sustained period to treat the targeted disease. Medgenics believes that this biological approach can replace a major portion of the regular and costly injections of therapeutic proteins patients currently receive.


The Company has demonstrated proof-of-principle of its treatment procedure in a clinical trial using EPODURE in anemic patients. A long-acting version of EPODURE designed to produce and deliver a therapeutic dose of EPO steadily for six months or more began Phase I/II efficacy trials in Israel in mid-2008. Clinical trials with INFRADURE are intended follow in due course.


Beyond this, the Company plans to develop a pipeline of products based on its Biopump technology targeting the large and rapidly growing global $50+ billion protein therapy market, which is expected to grow to some $132 billion per year in 2013.


Medgenics is managed by a highly experienced team of biotechnology and biomedical device experts, and its Board of Directors and Scientific Advisory Board include highly experienced figures in the healthcare industry, in healthcare finance, as well as influential figures from the medical community and academia.

Current Operations


The Medgenics’ Biopump technology is a combination biological/device product.


(a) The first stage is the removal (harvesting) of a sliver of dermal tissue, called a micro-organ (2-3mm diameter x 30-40mm length), from beneath the patient’s skin. This procedure is performed under a local anaesthetic, is intended to be performed in a physician’s office and is minimally invasive, so as to encourage rapid healing with little or no scarring. Generally, more than one micro-organ will be harvested from the patient (typically 4-5).


(b-e) The micro-organ is processed outside the body using a non-immunogenic adeno-viral vector to introduce the appropriate gene into the tissue’s cells and cause the cells to produce the desired protein, thus converting it into a sustained-action Biopump.


(f-i) Tests are performed during processing to determine the daily protein production from each Biopump. The appropriate number of Biopumps is thereby determined and then subcutaneously implanted back into the patient after one to two weeks.  After implantation, Biopumps are designed to maintain protein levels in the blood within the therapeutic window for up to six months or more.


Medgenics believes this technology can be applied across the large and rapidly growing global protein therapy market including the following:



Product Pipeline

Medgenics, Inc. has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, and is pleased to announce encouraging new results in the Company's ongoing Phase I/II clinical trial with our first product, the EPODURE Biopump, to treat anaemia. 


For more information please click here



Medgenics has now demonstrated proof of feasibility of long acting protein therapy from a single administration in a Phase I/II dose ranging clinical trial using EPODURE to produce and deliver erythropoietin (EPO) in a steady manner for up to 6 months in anemic patients.  To date, six patients have been treated in the low dose group (20 IU/kg/day) and one patient has been treated in the mid dose group (40 IU/kg/day), and most patients have shown an elevation of their baseline hemoglobin level and a steady maintenance of their hemoglobin levels within the target range. An excellent safety profile has also been demonstrated in all patients, with no adverse events reported.  The hospital ethical committee has declared EPODURE to be safe and effective even at the low dose. The Company's Strategic and Scientific Advisory Board noted that EPODURE is proving its potential as a superior treatment over serial injections for the treatment of chronic renal anemia.



Anemia is a condition in which the number of red blood cells or the hemoglobin in the red blood cells is below normal. This affects the distribution both of oxygen from the lungs to the tissues and of carbon dioxide back to the lungs for exhalation. Symptoms of anemia include weakness, pale skin, a fast heartbeat, shortness of breath, fatigue/exhaustion, chest pain, dizziness, cognitive problems, numbness or coldness in the extremities, and headaches.


Anemia is caused by, or associated with, a wide variety of conditions, ranging from chronic kidney disease and end-stage renal disease (e.g., in dialysis patients), to AIDS, hepatitis, cancer, chemotherapy, and other conditions. 


Erythropoietin (EPO) is a protein produced naturally in the kidneys that stimulates red blood cell production in the body. A shortage of EPO in the body can cause anemia, and therefore restoring EPO levels through multiple and frequent subcutaneous injections of recombinant EPO is the primary treatment.


Market Size

The U.S. National Kidney Foundation estimates that 20 million Americans suffer from chronic kidney disease and develop or are at risk for anemia. 2005 revenues of EPO exceeded $11 billion. EPO therapy is costly, requires serial multiple, painful injections, whose administration depends on patient compliance and has been reported to often result in unstable hematocrit and hemoglobin levels as well as side effects.



INFRADURE is Medgenics’ long-acting protein therapy designed to produce a sustained therapeutic dose of interferon-alpha (IFN-α) to treat hepatitis C. INFRADURE is scheduled to commence a Phase I/II trial in Israel during 2011. 


Hepatitis C

Hepatitis C is caused by the hepatitis C virus (HCV) and causes inflammation of the liver, chronic liver disease, cirrhosis and in 1%-5% of chronic cases, liver cancer over a period of 20 to 30 years.


Chronic HCV infection is the leading cause of liver disease in the U.S. and many other western countries. 


Market Size

Worldwide, it is estimated there are 170 million carriers of hepatitis C, with three to four million new infections annually. IFN-α is the leading therapy for chronic hepatitis C infection, but is effective in only 40%-50% of patients, and its administration by periodic injections is routinely accompanied by severe side effects associated with the temporary overdose of each bolus injected. 20%-50% of patients are reported to discontinue treatment as a result of treatment side effects.


In 2005, patients received $2.8 billion worth of IFN-α to treat hepatitis C and some forms of cancer, but there is an unmet need for an IFN-α therapy with greatly reduced side effects.







Michael F. Cola - President and Chief Executive Officer

Mr. Cola served as President of Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company, from 2007 until April 2012. He joined Shire in 2005 as EVP of Global Therapeutic Business Units and Portfolio Management. Prior to joining Shire, he was with Safeguard Scientifics, Inc., a growth capital provider to life sciences and technology companies, where he served as President of the Life Sciences Group. 

While at Safeguard, Mr. Cola served as Chairman and CEO of Clarient, Inc., a cancer diagnostics company subsequently acquired by GE Healthcare, and as Chairman of Laureate Pharma, Inc., a full-service contract manufacturing organization serving research-based biologics companies. Prior to Safeguard Scientifics, Mr. Cola held senior positions in product development and commercialization at AstraMerck, a top 20 U.S. pharmaceutical company, and at AstraZeneca, a global biopharmaceutical company.

Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University. He serves on the Board of Directors of Vanda Pharmaceuticals Inc., NuPathe Inc. and Pennsylvania BIO, the statewide association representing the bioscience community. He also currently serves as Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia.


John H. Leaman, M.D. - Chief Financial Officer

Dr. Leaman served as VP of Commercial Assessment at Shire plc, a global specialty pharmaceutical company, with responsibility for the strategic assessment of licensing and M&A opportunities, including Shire’s acquisition of SARcode Bioscience Inc. Prior to joining Shire in 2011, from 2007 to 2011, Dr. Leaman was a Principal at Devon Park Bioventures, a venture capital fund targeting investments in therapeutics companies, where he oversaw the fund’s investment and corporate board duties in life science investments including Proteon Therapeutics, Inc., Inotek Pharmaceuticals Corp., ZS Pharma, Inc. and MicuRx Pharmaceuticals, Inc. 

Prior to that, he was an Associate Principal at McKinsey & Company, where he provided consulting services to senior management of several top 20 pharmaceutical companies including M&A and corporate finance, payer/reimbursement strategies and strategic product development. 

He received an M.D. and an M.B.A. from the University of Pennsylvania’s School of Medicine and Wharton School, respectively. He received a degree in Psychology, Philosophy and Physiology at Oriel College, University of Oxford, while completing a Rhodes scholarship. Dr. Leaman received a B.S. in biology from Elizabethtown College.


Garry A. Neil, M.D. - Global Head Research and Development

Dr. Neil was a Partner at Apple Tree Partners, a life sciences private equity fund. Prior to joining Apple Tree Partners in 2012, he was Corporate VP of Science & Technology at Johnson & Johnson, and Group President at Johnson & Johnson Pharmaceutical Research and Development. Prior to joining Johnson & Johnson in 2002, he held senior positions at AstraZeneca, EMD Pharmaceuticals and Merck KGaA. Under his leadership a number of important new medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases gained initial or expanded approvals.

Dr. Neil holds a B.S. from the University of Saskatchewan and an M.D. from the University of Saskatchewan College of Medicine. He completed postdoctoral clinical training in internal medicine and gastroenterology at the University of Toronto. Dr. Neil also completed a postdoctoral research fellowship at the Research Institute of Scripps Clinic. He serves on the Boards of Reagan Udall Foundation and the Foundation for the U.S. National Institutes of Health (NIH), and is a member of the Science Management Review Board of the NIH. He is past Chairman of the Pharmaceutical Research and Manufacturers Association (PhRMA) Science and Regulatory Executive Committee and the PhRMA Foundation Board.

Eugene Andrew Bauer, M.D. - Executive Member of the Board of Directors 

Dr. Bauer has been a member of Medgenics' Board since March 2001. He has been Chairman of the Board since July 2005, assuming the role of Executive Chairman of the Board in October 2010. He is a Lucy Becker Emeritus Professor in the School of Medicine at Stanford University, having served as Dean of the Stanford University School of Medicine from 1995-2001 and as Chair of the Department of Dermatology at the Stanford University School of Medicine from 1988-1995.

Dr. Bauer is currently Chairman of the Board of Directors of Vyteris, Inc., a public company and the maker of the first FDA-approved ready-to-use drug delivery patch. He also serves as a director of a number of other life science and development stage biopharmaceutical companies and medical services companies, including privately held MediSync Bioservices and Dr. Tattoff, Inc. He was a co-founder and emeritus member of the board of directors of Connetics Corporation, a publicly traded, dermatology-focused therapeutics company which was acquired by Steifel Laboratories and sold to GlaxoSmithKline, Inc. He also served as a director of Protalex, Inc., Peplin Biotech, Ltd., PetDRx, Inc. and Modigene Inc., a life sciences company that is developing technology to lengthen the life of various proteins, including EPO and IFN-α.

For 25 years Dr. Bauer was an NIH-funded investigator and has served on review groups for the NIH. He has been elected to several societies including the Institute of Medicine of the National Academy of Sciences. Dr. Bauer received an M.D. from Northwestern University.


Clarence L. "Butch" Dellio - Chief Operating Officer

Mr. Dellio joined Medgenics in July 2011. He has been a consultant to a variety of emerging biotechnology and medical technology companies, providing facilities, manufacturing, clinical and regulatory expertise to therapeutics and diagnostics companies. 

From 2004 to 2008, Mr. Dellio served as President and Chief Operating Officer of Neosil, Inc., a venture-backed dermatology company that subsequently merged with Peplin, Inc. 

Prior to his position with Neosil, Mr. Dellio spent ten years at XOMA Ltd, a publicly held biotechnology company focused on peptides and monoclonal antibodies, where he served in a series of progressively responsible positions including Chief Financial Officer; Vice President Manufacturing; Senior Vice President Operations; and Chief Operating Officer. 

Previous positions included Vice President Manufacturing/New Product Development Manager at Becton-Dickinson & Company, a global medical technology company where Mr. Dellio spent 11 years. 

Mr. Dellio earned his Bachelor of Science in Accounting from Bentley College and served in the U.S. Air Force.


Stephen Bellomo, MsME - Vice President Product Development and Intellectual Property 

Mr. Bellomo has over ten years of experience in management roles in medical device and biotech industries. Prior to rejoining Medgenics in 2007, he was the CTO for Allium Medical, a urinary and gastrointestinal stent company, where he was responsible for all development and production activities. From 2006 to 2007, Mr. Bellomo was the Director of Special Projects for Glucon Medical, where he led the development of an automated glucose reader to support intensive insulin therapy in critical care applications. Mr. Bellomo held application development and marketing positions at Galil Medical, a cryosurgical device company. 

Mr. Bellomo received an MSc in Mechanical Engineering from The Technion Israel Institute of Technology, and a BE in Mechanical Engineering from The Cooper Union for the Advancement of Science and Art.


Nir Shapir, Ph.D. - Vice President of Reseach and Development

Dr. Shapir joined Medgenics in August 2010. From 2006-2010 he held various professional positions in the R&D Chemistry Assay Development Division of Beckman Coulter, Inc., Chaska, Minnesota, including Group Manager of Technology Development; Manager of Discovery and Technology; and Staff Development Scientist Team Leader.

Dr. Shapir received his Ph.D. from the Hebrew University of Jerusalem Faculty of Agriculture, Food and Environmental Quality Sciences. He was a Postdoctoral Associate in the Biochemistry, Molecular Biology & Biophysics Department and BioTechnology Institute of the University of Minnesota.


Phyllis K. Bellin MBA - Director of Finance & Administration 

Ms. Bellin received an MBA from Columbia University, New York and worked at Citibank (member of Citigroup Inc.) before coming to Israel in 1980. Since then, Ms. Bellin has managed finance and administration for several early stage, high-tech ventures in Israel. Most recently, she was a founder and vice president, finance and administration for Gintec Active Safety Ltd. and RoadEye Ltd.


Board of Directors


Sol J. Barer, Ph.D.  -  Chairman of the Board of Directors 


Eugene A. Bauer, M.D.  -  Director


Isaac Blech - Director


Alastair Clemow, Ph.D. -  Director


Michael F. Cola  -  President, Chief Executive Officer, and Director 


Wilbur H. (Bill) Gantz  -  Director


Joseph J. Grano, Jr. -  Director


Joel S. Kanter  -  Director 


Stephen D. McMurray, M.D. -  Director


Andrew L. Pearlman, Ph.D. -  Director and Senior Advisor


For more information please click here

Major Shareholders


Information taken from Company website 18.06.2013

  • Contact Information


    Medgenics, Inc.

    555 California Street, Suite 365

    San Francisco, California 94104

    Phone: +415.568.2245

    Fax: +415.568.2104




    Medgenics Medical Israel, Ltd.

    Misgav Business Park 

    Rechov Kahol 2

    P.O. Box 14

    Misgav 20179 Israel 

    Phone: +972.4.902.8900

    Fax: +972.4.999.0114


    Corporate Information

    Investor Relations  


    Teradion Business Park 

    P.O. Box 14

    Misgav 20179 Israel 

    Phone: +972.4.902.8900

    Fax: +972.4.999.0114




    Capita Registrars (Jersey) Limited

    12 Castle Street

    St Helier


    JE2 3RT

    Public Relations

    Abchurch Communications

    125 Old Broad Street

    London EC2N 1AR



    Nominated Advisors


    100 Cannon Street

    London EC4N 6EU, UK



    Nomura Code Securities Limited 

    1 Carey Lane 


    EC2V 8AE, UK 

    SVS Securities plc

    21 Wilson Street


    EC2M 2SN, UK


  • ProactiveInvestors on Facebook